ClonePix FL: powerful technology to explore cell surfaces and discover stellar clones. Select and isolate mammalian clones by cell surface protein expression, rapidly yielding monoclonal populations for cell based assays, screening and discovery research. Significantly improve timelines, labor costs and efficiency of cell line selection.
Wednesday, 3 October 2007
Nuclear Receptors in Liver and Digestive Diseases: A Research Workshop
Sponsored by: Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) and
Division of Digestive Diseases and Nutrition (DDN)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Description of the Meeting:
The nuclear receptor (NR) superfamily of transcriptional regulators has been integrally involved in the regulation of a variety of genes related to such diverse cellular and systems processes as the control of development to the regulation of bile acid and cholesterol biosynthesis. Disruption of the NR signaling pathways has been implicated in a variety of disease states such as diabetes, obesity, liver diseases such as non-alcoholic steatohepatitis, and other endocrine-related disorders. Many of the NR-implicated liver diseases are areas of high priority for research as outlined in the Trans-NIH Action Plan for Liver Disease Research (http://www.niddk.nih.gov/fund/divisions/ddn/ldrb/ldrb_action_plan.htm). Additionally, the NIDDK has recognized the importance of NRs in a variety of disease states and currently supports the Nuclear Receptor Signaling Atlas (http://www.nursa.org/index.cfm), an open access web portal for information about the NR superfamily.
This meeting will bring together scientists focused on the mechanisms and basic science of NR transcriptional regulation and translational and clinical investigators focused on the pathophysiology of digestive and liver disease states where an NR pathway has been implicated. Two keynote talks will cover the current basic understanding of NR regulation and the potential role of NR signaling dysregulation in the pathophysiology of disease conditions. Other talks will explore the known physiologic roles of ligands and receptors, such as sterol regulatory element-binding protein (SREBP), peroxisome proliferator-activated receptor (PPAR), retinoid X receptor (RXR), liver X receptor (LXR), and small heterodimer partner (SHP), and their downstream signaling in normal and in specific clinical conditions. The signaling mechanisms implicated in the development of obesity, non-alcoholic steatohepatitis, diabetes, bile acid and cholesterol synthesis dysregulation, and so on, also will be explored.
The aim of this meeting is to review the present state-of-the art knowledge of NRs, to promote cross-fertilization among the spectrum of basic, translational, and clinical investigators, and to integrate the current understanding of NR biology and the current clinical challenges for a variety of digestive and liver disease states. At the conclusion of the meeting, the organizers will define research challenges identified during the meeting. A meeting summary manuscript, including the research challenges identified, will be submitted for publication.
Organizers:
Edward Doo, Liver Disease Research Branch (LDRB), DDN, NIDDK
Ronald Evans, The Salk Institute for Biological Studies
Saul Karpen, Baylor College of Medicine
Joel Lavine, University of California at San Diego
Ronald Margolis, DEM, NIDDK
Patricia Robuck, LDRB, DDN, NIDDK
Locked Nucleic Acid-based arrays
The next generation of Exiqon's popular Locked Nucleic Acid-based arrays - the miRCURYTM LNA microRNA Array - is now available. With unmatched specificity, you can conduct expression profiling of a comprehensive range of microRNAs from any organism you like - vertebrates, invertebrates, plants and viruses, with unmatched sensitivity (sample from just 30 ng total RNA). You even have access to 150 proprietary microRNAs unavailable elsewhere (miRPlusTM). Our microRNA array platform is part of Exiqon's miRCURYTM product line, the most complete range of tools for microRNA analysis available today. The miRCURYTM tools enable you to seek, find and verify microRNAs - and to accelerate your discoveries.
www.exiqon.com/array-embo
Invitrogen Cellular Analysis 2007
The 2007 catalog from Invitrogen Cellular Analysis presents a broad portfolio of enabling inventions and their applications, brought together specifically to meet the challenges of examining biology in context. Order your copy today at www.invitrogen.com/cellsrock
Neuroscience Recruitment Advertising Package
Are you recruiting for researchers, post docs, faculty or staff in the field of neuroscience?
Satisfy your recruitment needs with our Neuroscience Recruitment Advertising Package!
Your advertisement will be featured in print in New Scientist magazine, the Neuron Special Supplement on Neuroscience Jobs & Trends, and online on ScienceJobs.com! Contact us at nssales@elsevier.com to learn about our discounted package rates and bonus distribution to the SfN Annual Meeting.
Transfection Research Award
Celebrate 10 Years of FuGENE® Reagents in Washington, D.C. in December!
Don't miss the chance to apply for the Transfection Research Award, and be eligible to win a trip to present your FuGENE® data at the 2007 ASCB Annual Meeting in Washington, D.C.!
Visit 10th Anniversary website for details and more information.
Additional GPCR Expressing Cell Lines Released
Lonza Releases Four New GPCR Expressing Cell Lines
| Now available! New cell lines for GPR103 and Vasopressin receptors V1a, V1b, and V2 allow you to evaluate excellent GPCR response levels at competitive prices. New receptors are available for the following therapeutic areas: increased feeding, blood pressure, bone formation, cell proliferation, glycogenolysis, and antidiuretic action. Please review these GPCRs or our growing list of other GPCR products by going to our e-catalog. Place an order for any of the 4 products listed in this e-mail by October 30, 2007 and reference the code GPCRT207 to receive a 15% discount from list price. GPR103 is a G-protein coupled receptor that has been shown to be expressed primarily in brain, heart, kidney, adrenal gland, retina and testis. Its ligand has been identified as a 43-residue RF-amide peptide known as QRFP. >> Human Vasopressin V1a Receptor Cell Line The pituitary hormone vasopressin (AVP) is a cyclic nonapeptide that acts by binding to a family of vasopressin receptors that includes the V1a, V1b, and V2 receptors. V1a receptors have been shown to be expressed in vascular smooth muscle, hepatocytes, various blood cells, brain, and retina. >> Human Vasopressin V1b Receptor Cell Line The pituitary hormone vasopressin (AVP) is a cyclic nonapeptide that acts by binding to a family of vasopressin receptors that includes the V1a, V1b, and V2 receptors. V1b receptors are expressed in the anterior pituitary where they mediate ACTH release. >> Human Vasopressin V2 Receptor Cell Line V2 receptors are expressed in the kidney where vasopressin exerts its antidiuretic action. |
Subscribe to:
Posts (Atom)